Platelet refractoriness
. | Pre-ULR group*(%) . | Post-ULR group*(%) . | P . |
|---|---|---|---|
| Overall refractoriness† | 27/315 (40) | 68/302 (23) | < .001§ |
| Overall alloimmune refractoriness‡ | 44/315 (14) | 12/302 (4) | < .001§ |
| Chemotherapy or supportive care patients | 19/116 (16) | 8/117 (7) | .038§ |
| ALL | 1/20 (5) | 1/11 (9) | .99∥ |
| AML | 13/84 (16) | 7/97 (7) | .097∥ |
| Supportive care | 5/12 (42) | 0/9 (0) | .045∥ |
| SCT patients | 25/199 (13) | 4/185 (2) | .003§ |
| ALLO RD | 7/75 (9) | 1/72 (1) | .063∥ |
| ALLO VUD | 8/39 (21) | 2/32 (6) | .102∥ |
| AUTO BM | 5/39 (13) | 1/24 (4) | .394∥ |
| AUTO PB | 5/46 (11) | 0/57 (0) | .016∥ |
| Nulliparous/nontransfused | 12/144 (8) | 3/152 (2) | .021§ |
| Parous/transfused | 28/154 (18) | 9/139 (7) | .005§ |
| Parous only | 5/46 (11) | 5/59 (9) | .75∥ |
| Transfused only | 15/75 (20) | 0/53 (0) | < .001∥ |
| Both | 6/26 (23) | 3/22 (12) | .47∥ |
. | Pre-ULR group*(%) . | Post-ULR group*(%) . | P . |
|---|---|---|---|
| Overall refractoriness† | 27/315 (40) | 68/302 (23) | < .001§ |
| Overall alloimmune refractoriness‡ | 44/315 (14) | 12/302 (4) | < .001§ |
| Chemotherapy or supportive care patients | 19/116 (16) | 8/117 (7) | .038§ |
| ALL | 1/20 (5) | 1/11 (9) | .99∥ |
| AML | 13/84 (16) | 7/97 (7) | .097∥ |
| Supportive care | 5/12 (42) | 0/9 (0) | .045∥ |
| SCT patients | 25/199 (13) | 4/185 (2) | .003§ |
| ALLO RD | 7/75 (9) | 1/72 (1) | .063∥ |
| ALLO VUD | 8/39 (21) | 2/32 (6) | .102∥ |
| AUTO BM | 5/39 (13) | 1/24 (4) | .394∥ |
| AUTO PB | 5/46 (11) | 0/57 (0) | .016∥ |
| Nulliparous/nontransfused | 12/144 (8) | 3/152 (2) | .021§ |
| Parous/transfused | 28/154 (18) | 9/139 (7) | .005§ |
| Parous only | 5/46 (11) | 5/59 (9) | .75∥ |
| Transfused only | 15/75 (20) | 0/53 (0) | < .001∥ |
| Both | 6/26 (23) | 3/22 (12) | .47∥ |
Abbreviations are explained in Table 2.
Number of refractory patients/total number of patients in the group.
There were 2 consecutive corrected count increments of less than 5.
Refractoriness within 2 weeks of 2 or more consecutive positive lymphocytotoxicity screens.
Chi-square test.
Fisher exact test.